ArticleNanomaterials (Basel, Switzerland)2022
Curcumin-Loaded Human Serum Albumin Nanoparticles Prevent Parkinson's Disease-like Symptoms in
Article in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Antitumor Activity of All-Trans Retinoic Acid and Curcumin-Loaded BSA Nanoparticles Against U87 Glioblastoma Cells.Life (Basel, Switzerland) · 2026Article
- Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead.AAPS PharmSciTech · 2025Review
- A novel scalable method for the production of rennet-treated milk-derived extracellular vesicles for improved curcumin oral delivery.Journal of nanobiotechnology · 2025Article
- Development of an Innovative Nanosystem Based on Functionalized Albumin and Oxidized Gellan for the Synergistic Delivery of Curcumin and Temozolomide in the Treatment of Brain Cancer.Gels (Basel, Switzerland) · 2025Article
- Curcumin Promotes the Recovery of Motor Function After Brachial Plexus Avulsion Injury in Rats.Brain and behavior · 2025Article
- Experimental Models and Their Applicability in Inflammation Studies: Rodents, Fish, and Nematodes.International journal of molecular sciences · 2025Review
- Nanostructure Lipid Carrier of Curcumin Co-Delivered with Linalool and Geraniol Monoterpenes as Acetylcholinesterase Inhibitor ofMolecules (Basel, Switzerland) · 2024Article
- Nicotine-mediated therapy for Parkinson's disease in transgenicFrontiers in aging neuroscience · 2024Article
- Curcumin, inflammation, and neurological disorders: How are they linked?Integrative medicine research · 2023Review
- Role of Polyanions and Surfactant Head Group in the Formation of Polymer-Colloid Nanocontainers.Nanomaterials (Basel, Switzerland) · 2023Article
- Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review.Pharmaceutics · 2023Review
- The impact of curcumin on livestock and poultry animal's performance and management of insect pests.Frontiers in veterinary science · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Parkinson's disease is one of the most common degenerative disorders and is characterized by observable motor dysfunction and the loss of dopaminergic neurons. In this study, we fabricated curcumin nanoparticles using human serum albumin as a nanocarrier. Encapsulating curcumin is beneficial to improving its aqueous solubility and bioavailability. The curcumin-loaded HSA nanoparticles were acquired in the particle size and at the zeta potential of 200 nm and -10 mV, respectively. The curcumin-loaded human serum albumin nanoparticles ameliorated Parkinson's disease features in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.